# Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients

> **NCT05046665** · PHASE1 · COMPLETED · sponsor: **South Metropolitan Health Service** · enrollment: 11 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** 89Zr-Girentuximab

## Key facts

- **NCT ID:** NCT05046665
- **Lead sponsor:** South Metropolitan Health Service
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-14
- **Primary completion:** 2022-08-09
- **Final completion:** 2022-08-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05046665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05046665, "Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05046665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*